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TOR Regulates Ribosomal Protein Gene Expression
via PKA and the Forkhead Transcription Factor FHL1
sponse to nutrients (Gingras et al., 2001; Harris and
Lawrence, 2003; Jacinto and Hall, 2003; Schmelzle and
Hall, 2000). As a central controller of cell growth, TOR
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regulates several growth-related processes includingBiozentrum
ribosome biogenesis. In S. cerevisiae, RNA Pol I- andUniversity of Basel
RNA Pol III-dependent transcription and 35S rRNA pro-Klingelbergstrasse 70
cessing are strongly reduced upon TOR inhibition byCH-4056 Basel
rapamycin treatment. Moreover, rapamycin treatmentSwitzerland
leads to a rapid and pronounced downregulation of RNA
Pol II-dependent RP genes (Hardwick et al., 1999; Pow-
ers and Walter, 1999; Schmelzle et al., 2004; ShamjiSummary
et al., 2000; Zaragoza et al., 1998). Thus, TOR broadly
controls ribosome biogenesis. Rapamycin-induceddown-The regulation of ribosome biogenesis in response to
regulation of ribosomal genes (RP, rRNA, and tRNAenvironmental conditions is a keyaspect of cell growth
genes) is suppressed by activation of the RAS-cAMP-control. Ribosomal protein (RP) genes are regulated by
PKA pathway. Furthermore, TOR controls the subcellu-the nutrient-sensitive, conserved target of rapamycin
lar localization of PKA and the PKA-regulated kinase(TOR) signaling pathway. TOR controls the subcellular
YAK1. These results suggest that TOR controls ribo-localization of protein kinase A (PKA) and the PKA-
some biogenesis via the RAS-cAMP-PKA pathwayregulated kinase YAK1. However, the target transcrip-
(Schmelzle et al., 2004). However, the target transcrip-tion factor(s) of the TOR-PKA pathway are unknown.
tion factor(s) and regulatory mechanism by which TOR-We show that regulation of RP gene transcription via
PKA controls ribosomal gene expression are unknown.TOR and PKA in yeast involves the Forkhead-like tran-
Several transcription factors have been implicated inscription factor FHL1 and the two cofactors IFH1 (a
the regulated expression of ribosomal genes. The rapa-coactivator) and CRF1 (a corepressor). TOR, via PKA,
mycin-sensitive transcription factor RRN3 mediates Polnegatively regulates YAK1 and maintains CRF1 in the
I-dependent transcription in yeast and mammalian cellscytoplasm. Upon TOR inactivation, activated YAK1
(Claypool et al., 2004; Fath et al., 2001;Mayer et al., 2004;phosphorylates and activates CRF1. Phosphorylated
Nomura, 2001; Peyroche et al., 2000). Upon rapamycinCRF1 accumulates in the nucleus and competes with
treatment, RRN3 dissociates from rRNA promoters andIFH1 for binding to FHL1 at RP gene promoters, and
exits the nucleolus. The multifunctional ABF1 and RAP1thereby inhibits transcription of RP genes. Thus, we
proteins directly control Pol II-dependent RP gene ex-describe a signaling mechanism linking an environ-
pression, but the binding of at least RAP1 to RP promot-mental sensor to ribosome biogenesis.
ers is unaffected by nutrient limitation or rapamycin
treatment (Reid et al., 2000; Rohde and Cardenas, 2003).Introduction
The two histone H4 modifying factors ESA1, a histone
acetylase subunit of NuA4, and RPD3, a histone deacet-Cell growth (increase in cell mass) is controlled in re-
ylase subunit of the RPD3-SIN3 complex, have beensponse to nutrients, growth factors, and other environ-
implicated in the activation and repression of RP genes,mental conditions. A key component of cell growth con-
respectively. ESA1 binds and activates RP genes undertrol is the regulation of ribosome biogenesis, not only
good nutrient conditions, but is rapidly released from
because ribosomes are directly required for growth, but
RP gene promoters upon starvation or TOR inactivation
also because ribosome biogenesis is a major consumer
by rapamycin (Reid et al., 2000; Rohde and Cardenas,
of cellular energy. Tomaintain robust growth in response 2003). Conversely, RPD3 binds and inhibits RP and 35S
to favorable conditions, cells synthesize approximately rRNA genes upon TOR inactivation (Humphrey et al.,
2000 ribosomes per minute. This requires the coordi- 2004; Rohde and Cardenas, 2003; Tsang et al., 2003).
nated activity of all three RNA polymerases transcribing Recently, the transcription factor SFP1 has also been
several hundred genes, including 35S rRNA genes by shown to bind and regulate RP gene promoters in a
Pol I, ribosomal protein (RP) genes by Pol II, and 5S TOR-dependent manner (Marion et al., 2004; Jorgensen
rRNA and tRNA genes by Pol III (Jorgensen et al., 2004b; et al., 2004a). The mechanism by which these factors
Nomura, 2001; Warner, 1999). Thus, in a growing cell, are controlled either directly or indirectly by TOR is un-
approximately 95% of total transcription and a large known.
portionof total cellular energy arededicated to ribosome A genome-wide transcription factor binding study re-
biogenesis, underscoring the need for tight regulation cently revealed that the Forkhead-like, presumed tran-
of ribosomal genes in response to nutrient and energy scription factor FHL1 is highly enriched at yeast RP gene
conditions. Despite the fundamental importance of this promoters (Bar-Joseph et al., 2003; Lee et al., 2002).
regulation, it is poorly understood. FHL1 was originally discovered as a multicopy suppres-
The highly conserved protein kinase TOR and its sor of amutation in RNAPol III. An FHL1deletion confers
namesake signaling network control cell growth in re- a very slow growth phenotype and a defect in 35S rRNA
processing (Hermann-Le Denmat et al., 1994). Further-
more, FHL1 interacts with the Pol I transcription factor*Correspondence: m.hall@unibas.ch
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HMO1 (Ho et al., 2002; Ito et al., 2001). These findings region of 69 amino acids (IFH1 amino acids 673–741,
CRF1 amino acids 340–408) (see Supplemental Figuresuggest that FHL1 is a potential regulator of ribosome
biogenesis and possibly a target of TOR signaling. The S1 available at http://www.cell.com/cgi/content/full/
119/7/969/DC1/). The FHB domains of IFH1 and CRF1essential protein IFH1 (interacting with Forkhead 1 ) was
identified as a weak multicopy suppressor of an FHL1 interacted with the FHA domain of FHL1 (Figures 1B
and 1C). The FHB domains of IFH1 and CRF1 failed todeletion (Cherel and Thuriaux, 1995), but the function
of IFH1 and the significance of its genetic interaction interact with the FHA domain of the yeast Forkhead
factor FKH1, as assessedbya two-hybrid assay, indicat-with FHL1 are unknown.
In this study, we show that regulation of RP gene ing that the FHB domains of IFH1 and CRF1 bind specifi-
cally to the FHA domain in FHL1 (data not shown). Intranscription via TOR and PKA involves the Forkhead
factor FHL1 and the two cofactors IFH1 (a coactivator) summary, FHB domains in IFH1 and CRF1 bind the FHA
domain in FHL1.and CRF1 (a corepressor). TOR controls RP gene tran-
scription by maintaining CRF1 in the cytoplasm. Upon
TOR inhibition, phosphorylated CRF1 rapidly translo- TOR Inversely Regulates the Binding of IFH1
cates into the nucleus, competes with IFH1 for binding and CRF1 to FHL1
to FHL1 at RP gene promoters, and thereby inhibits To investigate if FHL1 is a target of TOR signaling, we
transcription of RP genes. Importantly, CRF1 is phos- examined if TOR regulates the interaction of IFH1 or
phorylated in vivo and in vitro by the TOR- and PKA- CRF1 with FHL1 (Figure 2A). The interactions were as-
regulated kinase YAK1. Thus, we describe a novel path- sessed using a coimmunoprecipitation assay and ex-
way from a nutrient sensor to the regulated expression tracts from rapamycin-treated or -untreated cells ex-
of ribosomal genes. pressing epitope-tagged versions of FHL1 and IFH1 or
CRF1 (see Experimental Procedures). FHL1 and IFH1
coimmunoprecpitated, but only in extracts from rapa-Results
mycin-untreated cells. Conversely, FHL1 and CRF1 also
coimmunoprecipitated, but only in extracts from rapa-FHL1 Interacts with IFH1 and CRF1
mycin-treated cells. Thus, TORpromotes the FHL1-IFH1To understand how the TOR-PKA pathway regulates
interaction and inhibits the FHL1-CRF1 interactionexpression of ribosomal genes, we focused on the pre-
in vivo, suggesting that FHL1 is indeed a target of TORsumed transcription factor FHL1 as a candidate target.
signaling. Furthermore, the finding that the binding ofTo investigate the function and regulation of FHL1, we
IFH1 and CRF1 to FHL1 appears to be mutually exclu-first performed a yeast two-hybrid screen to identify
sive, combined with the earlier finding that a domainpotential FHL1 cofactors. The N-terminal, middle, and
(FHB) common to both IFH1 and CRF1 binds the sameC-terminal regions of FHL1 were used separately as bait
domain (FHA) in FHL1, suggests that IFH1 and CRF1(Figure 1A). The middle (M) region of FHL1 repeatedly
compete with each other for binding to FHL1. The aboveand exclusively identified two interactors (each 10
results also confirm the interactions of FHL1 with IFH1times), IFH1 and the previously uncharacterized open
and CRF1 originally detected with the two-hybrid assay.reading frame YDR223W (Figure 1A). These interactions
were confirmed by coimmunoprecipitation, as de-
scribed below. YDR223W was named CRF1 (corepres- TOR Inversely Regulates FHL1-Dependent
Recruitment of IFH1 and CRF1 to RP Gene Promoterssor with FHL1 ), for reasons also described below. A
more detailed mapping of the interaction site in FHL1 To investigate the functional consequence of IFH1 and
CRF1 binding to FHL1, we examined the ability of FHL1,revealed that residues 270–450 of FHL1 mediate the
binding to IFH1 orCRF1 (Figure 1B). This region contains IFH1, and CRF1 to bind an RP gene promoter. Binding
of FHL1, IFH1, and CRF1 to the RPL30 promoter wasa conserved Forkhead-associated (FHA) domain (amino
acids 300–450). FHA domains mediate protein-protein examined in rapamycin-treated and -untreated cells us-
ing a chromatin-immunoprecipitation (ChIP) assay (seeinteractions in functionally diverse proteins in pro- and
eukaryotes (Durocher and Jackson, 2002). Substitution Experimental Procedures) (Figure 2B). FHL1 bound to
the RPL30 promoter in both rapamycin-treated andof FHL1 glycine 303, a residue conserved in all FHA
domains, to alanine abolished the interaction with both -untreated cells, confirming a previous report that FHL1
is constitutively bound to RP gene promoters (Bar-IFH1 and CRF1. The above results indicate that the FHA
domain of FHL1 is necessary and sufficient for binding to Joseph et al., 2003). IFH1 bound to the RPL30 promoter
but only in rapamycin-untreated cells. Conversely, CRF1IFH1 and CRF1 (Figure 1B). The DNA binding, Forkhead
homology (FH) domain (also called FOXdomain) of FHL1 bound to the RPL30 promoter only in rapamycin-treated
cells. The inversely regulated binding of IFH1 and CRF1was not required for the interaction with IFH1 or CRF1
(Figure 1B). to the RPL30 promoter reflects the binding of these two
proteins to FHL1, suggesting that the binding of IFH1Inspection of the many isolated IFH1 and CRF1 prey
plasmids delineated the regions in IFH1 and CRF1 re- and CRF1 to the promoter is FHL1-dependent. To inves-
tigate if the binding of IFH1 and CRF1 to the RP genequired for interaction with FHL1. IFH1 and CRF1 inter-
acted with FHL1 via an internal region common to both promoter is FHL1-dependent, we examined promoter
binding of IFH1 and CRF1 in an FHL1 deletion (fhl1)proteins. We refer to this homologous region as the
Forkhead-binding (FHB) domain. The FHB domains fall strain. Binding of neither IFH1 nor CRF1 to the RPL30
promoter was detected in the fhl1 strain either treatedwithin amino acids 644–800 of IFH1 (1086 total residues)
and amino acids 279–467 of CRF1 (467 total residues). or untreated with rapamycin, indicating that IFH1 and
CRF1 require FHL1 for promoter binding (Figure 2B).The two FHB domains display 59% identity over a core
TOR Controls Ribosome Biogenesis
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Figure 1. FHA Domain of FHL1 Binds the
FHB Domains of IFH1 and CRF1
(A) FHL1 bait constructs used in the yeast
two-hybrid screen. IFH1 and CRF1 (alias
YDR223W) were isolated as interactors with
the middle (M) fragment of FHL1.
(B) The Forkhead-associated (FHA) domain
of FHL1 interacts with the FHB domains of
IFH1 and CRF1. Different regions of FHL1
were assayed for interaction with the FHB
domain of IFH1 (IFH1(644–800)) and the FHB do-
main of CRF1 (CRF1(279–467)). The regions of
FHL1 that were assayed for interaction were
FHL1-M(270–570), FHA(267–450), FHAcore(300–420),
FHA(267–450) containing the G303A mutation
(FHAG303A), and FH(451–560).
(C) Highly conserved core region of IFH1 and
CRF1 FHB domains is not sufficient for inter-
action with the FHL1 FHA domain. All interac-
tions were assessed with the two-hybrid
assay, and quantified using a -galactosi-
dase (lacZ) reporter.
Thus, by controlling the FHL1-IFH1 and FHL1-CRF1 in- additional, TOR-controlled factors such as SFP1 or
RPD3. Interestingly, fhl1 cells displayed a reducedteractions, TOR controls the binding of IFH1 and CRF1
to RP gene promoters. level of RP gene expression that was not further de-
creased uponTOR inactivation, indicating thatRPgenesTodetermine if RPpromoter bindingof IFH1 andCRF1
is regulated in response to a physiologically relevant can be neither activated nor repressed in cells lacking
FHL1. A deletion of or a missense mutation (G303A) incue,we examinedpromoter binding in response to nutri-
ent deprivation, in particular, glucose limitation. Similar the FHA domain of FHL1 caused the same phenotype
as observed with a complete FHL1 null mutation (fhl1)to the above results with rapamycin treatment, glucose
limitation caused IFH1dissociation fromandCRF1bind- (data not shown), suggesting that the interactions medi-
ated by the FHA domain are essential for FHL1 function.ing to the RPL30 promoter (Figure 2B). Thus, TOR ap-
pears to control RP promoter binding of IFH1 and CRF1 The above phenotypes conferred by a crf1 or fhl1
mutation were abrogated upon complementation of thein response to the carbon source and possibly other
nutrient signals. mutation with a wild-type, plasmid-borne version of the
corresponding gene. The above findings taken together
suggest that CRF1 is a corepressor with FHL1 of RPCRF1 Is a Corepressor with FHL1 of RP Genes
The above finding that CRF1 binds FHL1 and thereby genes.
To investigate further the role of CRF1 in the TORRPgene promoters only in rapamycin-treated or starved
cells (i.e., when RP genes are repressed) suggested that pathway, we examined if a CRF1 deletion confers rapa-
mycin resistance (Figure 3C). A crf1 gat1 gln3 strainCRF1 is a negative regulator of RP genes. To determine
if CRF1 is a repressor, we examined expression of sev- was generated for this purpose, because the GAT1 and
GLN3 transcription factors independently inhibit growtheral RP genes (RPL30, RPL19A, RPL16A, RPL9A,
RPS26A, and RPS11A) in wild-type and crf1 cells upon TOR inactivation and would thus mask a potential
rapamycin-resistance phenotype conferred by crf1treated and untreated with rapamycin. In wild-type cells,
all RP genes were strongly downregulated within 30 (Beck and Hall, 1999; Schmelzle et al., 2004). crf1 con-
ferred pronounced rapamycin resistance in the other-min of rapamycin treatment. However, in crf1 cells,
rapamycin had a minor effect; all RP genes remained wise rapamycin-sensitive gat1 gln3 background.
Deletion of RPD3, encoding a histone deacetylase pre-highly expressed after rapamycin treatment, although
minor repression was still observed (Figures 3A and 3B, viously implicated inRPgene expression, also conferred
strong rapamycin resistance in the gat1 gln3 back-and data not shown). The minor repression observed
in the rapamycin-treated crf1 cells could be due to ground. Deletion of HOS2, encoding a functionally unre-
Cell
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Figure 2. TOR Controls Binding of IFH1 and
CRF1 to FHL1 and RP Gene Promoter
(A) TOR promotes the association of IFH1
with FHL1 and inhibits the association of
CRF1 with FHL1. Strains DM64-10B (FHL1-
myc IFH1-HA) and DM63-7A (FHL1-myc
CRF1-HA) were grown in YPD to midlog
phase, treated for 30 min with rapamycin ()
or drug vehicle alone () and protein interac-
tions were analyzed by coimmunoprecipita-
tion. Indicated are proteins immunoprecipi-
tated (IP) and subsequently probed by
Western blot (BLOT) with antibodies against
corresponding epitope tags. A rapamycin-
induced reduction in IFH1 protein level was
consistently observed.
(B) TOR promotes IFH1 binding to RP gene
promoters and inhibits CRF1 binding to RP
gene promoters. The binding of IFH1 and
CRF1 to RP gene promoters is FHL1-depen-
dent. Cells were grown in YPD to midlog
phase, treated for 30 min with rapamycin ()
or drug vehicle alone (), and processed for
chromatin immunoprecipitation as described
in Experimental Procedures. For glucose
starvation, cells were grown in SD medium
containing 0.2% yeast extract and shifted to
SC medium containing 0.2% yeast extract,
but without glucose, for 1 hr and processed
as described above. FHL1 and IFH1 were im-
munoprecipitated from wild-type (WT) strain
DM64-10B (FHL1-myc IFH1-HA). CRF1 was
immunoprecipitated from wild-type strain
(WT) DM63-7A (FHL1-myc CRF1-HA). IFH1
and CRF1 were immunoprecipitated from FHL1 deletion strains (fhl1) DM61-9D (fhl1 IFH1-HA) and DM62-5C (fhl1 CRF1-HA), respectively.
The chromatin immunoprecipitation was probed for the presence of the RPL30 promoter by PCR with primers that hybridize to positions
550 and 120 relative to the ATG start codon. The RPL30 promoter contains two putative FHL1 binding sites as judged by comparison to
a published putative FHL1 consensus binding site (Cliften et al., 2003; Kellis et al., 2003). T, total chromatin input; IP, ChIP with antibody
against the protein listed on the left side of the figure; -Ab, control ChIP in the absence of antibody.
lated histone deacetylase, did not confer rapamycin tional activator. Furthermore, they suggest that the
N-terminal domain of IFH1 may function as an activa-resistance but did stimulate the appearance of sponta-
neous rapamycin-resistant mutants (Figure 3C). Thus, tion domain.
To determine if IFH1 is an activator of RP genes, weas rapamycin resistance is the expected phenotype due
to the loss of a repressor in the TOR pathway, both examined if IFH1 overexpression prevents CRF1-medi-
ated repression of RP genes. Rapamycin treatmentCRF1 and the histone deacetylase RPD3 appear to have
negative roles in TOR signaling. failed to downregulate RP gene expression in cells con-
taining the IFH1 gene on a multicopy plasmid (Figure
4B). Overexpression of IFH1-FHB did not counter the
IFH1 Is a Coactivator of RP Genes
effect of rapamycin on RP gene expression. Finally, we
The above finding that IFH1 binds FHL1 and thereby RP
also used an IFH1 gene driven by the strong, galactose-
gene promoters only in rapamycin-untreated cells (i.e.,
inducible GAL1 promoter to analyze the effect of dif-
when RP genes are expressed) suggested that IFH1 is
ferent IFH1 protein levels on RP gene transcription. Ga-
a positive regulator of RP genes. To determine if IFH1
lactose induction (60 min) of IFH1 led to a significant
is an activator, we could not simply examine RP gene
induction of RP genes (Figure 4C). The above findings
expression in an ifh1 strain because IFH1 is essential.
taken together indicate that IFH1 is a coactivator with
Instead, we tested if IFH1 can activate a heterologous,
FHL1 of RP genes, and further suggest that IFH1 and
GAL4-driven promoter. Wild-type IFH1 or deletion vari-
CRF1 compete with each other for binding to FHL1.
ants of IFH1 lacking the FHB domain (IFH1-FHB) or an
N-terminal acidic domain (IFH1-N) were overexpressed
in cells coexpressing the FHL1-FHA domain fused to TOR Negatively Regulates Nuclear
Localization of CRF1the GAL4 DNA binding domain (FHL1-FHA-GAL4-DBD).
AGAL4-driven lacZ reporter genewas used as a readout To investigate the mechanism by which TOR regulates
the competitive binding of the IFH1 coactivator and theof IFH1-dependent transcriptional activation. Wild-type
IFH1 strongly activated lacZ expression (Figure 4A). CRF1 corepressor to FHL1, we examined the localiza-
tion of these proteins in rapamycin-treated and -un-IFH1-FHB failed to activate lacZ expression. Interest-
ingly, IFH1-N weakly activated the reporter gene. treated cells. The cellular localization of epitope-tagged
FHL1, IFH1, and CRF1 was examined by indirect immu-These results suggest that IFH1 is indeed a transcrip-
TOR Controls Ribosome Biogenesis
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Figure 3. CRF1 Is a Negative Regulator
(A) CRF1 is a repressor of RP gene expres-
sion. Northern blot analysis was performed
using cells (WT, TB50a; fhl1, DM46-4A; crf1,
DM45-2C) grown in YPD to midlog phase and
either treated with rapamycin () or drug ve-
hicle alone () for 30 min. RNA was extracted
and Northern analysis performed using a
probe against RPL30.
(B) Kinetics of RP gene repression in re-
sponse to rapamycin. Quantification of rela-
tive RPS26 and RPL30 mRNA levels from
three independent Northern blot experiments
with rapamycin-treated and -untreated TB50a
(WT) and DM45-2C (crf1).
(C) Deletion of CRF1 (crf1) or RPD3 (rpd3)
confers rapamycin resistance. Deletion of
BCY1 (bcy1), YAK1 (yak1) also confers rapa-
mycin resistance asshownpreviously (Schmel-
zle et al., 2004). All strains except wild-type
(WT) and TOR1-1 contain deletions of both
GAT1 and GLN3 (gat1 gln3). Strains were
grown on YPD plates with () or without ()
rapamycin (200 ng/ml) for 5 days. Strains
were as follow: WT, TB50a; TOR1-1, DM72-
7A; bcy1, TS160-6C; yak1, TS135-2C; crf1,
DM76-3B; rpd3, DM81-3A; hos2, DM80-8C.
nofluorescence onwhole fixed cells. Consistent with the this question, we investigated if an activated RAS-PKA
pathway prevents rapamycin-induced nuclear localiza-above observation that FHL1 is constitutively bound to
tion of CRF1. To activate the RAS-PKA pathway, weRP gene promoters, FHL1 was concentrated in the nu-
knocked out the gene (BCY1) encoding the negativecleus in both rapamycin-treated and -untreated cells
regulatory subunit of PKA or introduced an activated(data not shown). IFH1 was also nuclear under both
allele of RAS2 (RAS2Val19). Rapamycin failed to induceconditions (data not shown). CRF1, however, wasmainly
nuclear localization of CRF1 in both bcy1 and RAS2Val19cytoplasmic in rapamycin-untreated cells but rapidly ac-
cells (Figure 5B). Rapamycin also failed to induce nu-cumulated in the nucleus upon rapamycin treatment
clear translocation of CRF1 in cells containing a rapa-(Figure 5A). CRF1 was essentially entirely nuclear within
mycin-resistanceTOR1 (TOR1-1) allele. To further inves-20 to 30 min of rapamycin treatment. The localization
tigate a role for the RAS-PKA pathway, we examinedof CRF1 in rapamycin-treated or -untreated fhl1 cells
CRF1 localization in the temperature sensitive cdc25-5was as described above for wild-type cells, indicating
and cdc35-10mutants. CDC25 is the guanine nucleotidethat CRF1 nuclear localization was not FHL1-dependent
exchange factor required for RAS2 activation, and(data not shown). As expected from the above finding
CDC35/CYR1 is adenylate cyclase required for cAMPthat CRF1 binding to an RP gene promoter is induced
production and PKA activation. Upon inactivation ofupon glucose starvation, carbon source limitation also
CDC25 and CDC35 by shifting the cdc25-5 and cdc35-induced nuclear localization of CRF1 (see Supplemental
10 mutants to nonpermissive temperature, CRF1 accu-Figure S2 available on Cell website). Interestingly, CRF1
mulated in the nucleus (see Supplemental Figure S3required its FHBdomain for nuclear localization, indicat-
available on Cell website). These results suggest thating that the FHB domain has a dual role as an FHL1
TOR signals to CRF1, and ultimately FHL1, via the RAS-interaction domain and as a signal for nuclear import or
PKA effector pathway. However, we cannot exclude theretention (Figure 5A). Thus, TOR appears to regulate
possibility that CRF1 localization is controlled by PKAthe competitive binding of IFH1 and CRF1 to FHL1 by
in a TOR-independent fashion. Further evidence thatrestricting access of CRF1 to FHL1 in the nucleus.
TOR signals to CRF1 via PKA is provided by the below
finding that CRF1 is controlled by YAK1.
TOR Controls CRF1 via the RAS-PKA Pathway
Previous findings indicated that TOR controls RP gene YAK1 Phosphorylates and Activates CRF1
expression via the RAS-PKA pathway (Schmelzle et al., PKA negatively regulates, probably directly, the dual-
specificity protein kinase YAK1 (Garrett and Broach,2004). Does TOR control CRF1 via RAS-PKA? To answer
Cell
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Figure 4. IFH1 Is a Transcriptional Activator
(A) IFH1 activates transcription of a heterolo-
gouspromoter. IFH1was recruited to aGAL4-
driven, heterologous promoter via interaction
with the FHL1-FHA domain fused to the GAL4
DNA binding domain. Strain PJ69-4A, ex-
pressing a hybrid protein consisting of the
FHL1-FHA domain fused to the GAL4 DNA
binding domain (pDM103), was transformed
with a plasmid containing full-length IFH1
(pSA001) or the IFH1 deletion variant IFH1-
N (pSA002) or IFH1-FHB (pSA003) or the
empty vector (pHAC181). Activation was as-
sayed as expression of the lacZ reporter
gene.
(B) Multicopy IFH1 counters rapamycin-
induced repression of RP genes. Northern
blot analysis was performed on wild-type
cells (TB50a) harboring a multicopy plasmid
containing either full-length IFH1 (IFH1) or the
IFH1-FHB deletion variant. Cells were
grown in SD medium to midlog phase and
treated with rapamycin or drug vehicle alone
for 30 min. RNA was extracted and Northern
analysis performed using a probe against
RPL30.
(C) Transcriptional induction of IFH1 under
control of a heterologous promoter induces
RP gene transcription. IFH1 under control of
the strong, galactose-inducible GAL1 pro-
moter was induced by shifting cells from raffi-
nose (Raff) to galactose (Gal). Strains DM70-
1B (IFH1 driven by the GAL1 promoter) and TB50a (WT) were grown in YPRaffinose medium to an OD of 0.5, filtered, resuspended in
YPGalactose, and incubated for an additional 1 or 2 hr. RNA was extracted and Northern analysis was performed using a probe against RPL30.
1989; Griffioen et al., 2001; Moriya et al., 2001; Zappa- -untreated yeast cells. GST-tagged CRF1-FHB domain
was purified from E. coli cells. myc-YAK1 isolated fromcosta et al., 2002). Furthermore, TOR controls YAK1
localization, and a YAK1 deletion confers rapamycin re- rapamycin-treated cells, but not from rapamycin-
untreated cells, strongly phosphorylated GST-taggedsistance (Schmelzle et al., 2004) (Figure 3B). These find-
ings suggest that TOR and PKA may control CRF1 via CRF1-FHB but not GST or BSA (Figure 6C and data not
shown). A mock purification of untagged YAK1 fromYAK1. More specifically, they suggest that YAK1 may
activate CRF1 upon reduced signaling through the TOR- either rapamycin-treated or -untreated cells failed to
yield any kinase activity toward any of the examinedPKA pathway. To investigate this possibility, we first
examined if YAK1 has a role in downregulating RP gene substrates (Figure 6Canddata not shown). Furthermore,
kinase dead (K398R) YAK1 (YAK1KD) purified from rapa-expression upon TOR inactivation. A YAK1 deletion pre-
vented rapamycin-induced nuclear localization of CRF1 mycin-treated cells failed to phosphorylate CRF1-FHB,
indicating that YAK1 and not a copurifying kinase phos-and downregulation of RPL30, RPL16, and RPS26 (Fig-
ures 5B and 6A). Thus, upon TOR inactivation, YAK1 phorylated CRF1-FHB (Figure 6D). YAK1KD also failed
to promote nuclear localization of CRF1 in rapamycin-appears to activate CRF1 and, thereby, to negatively
regulate RP gene expression. treated cells (data not shown), suggesting that YAK1
kinase activity is required for CRF1 regulation. YAK1To investigate further the control of CRF1 by YAK1,
we examined if YAK1 phosphorylates CRF1 in a TOR- autophosphorylates on one or more tyrosine residues
(Moriya et al., 2001), and we also detected rapamycin-sensitive manner. CRF1 was immunoprecipitated from
rapamycin-treated and -untreated wild-type and yak1 induced YAK1 autophosphorylation on tyrosine resi-
dues (Figure 6C). These results suggest that YAK1 spe-cells, and subsequently probed with antiphosphothreo-
nine antibodies. Threonine-phosphorylated CRF1 was cifically phosphorylates and thereby activates CRF1
directly. Furthermore, the observation that YAK1 auto-detected only in rapamycin-treated, wild-type cells (Fig-
ure 6B), suggesting that YAK1 phosphorylates CRF1 phosphorylation is rapamycin-induced suggests that
the TOR-PKA pathway negatively controls intrinsicin vivo.
To investigate if YAK1 phosphorylates and thus con- YAK1 kinase activity.
trols CRF1 directly, we examined if purified YAK1 phos-
phorylates purified CRF1 FHB domain in vitro (see Discussion
Experimental Procedures). We speculated that YAK1
phosphorylates the Forkhead binding (FHB) domain of We have presented several observations indicating that
TOR controls the expression of ribosomal protein genesCRF1 because this domain mediates the regulated nu-
clear import and FHL1 binding of CRF1. myc-tagged via the Forkhead transcription factor FHL1. Furthermore,
our findings provide a molecular mechanism by whichYAK1 was immunopurified from rapamycin-treated and
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Figure 5. TOR Controls CRF1 Nuclear Local-
ization via the RAS-PKA Pathway
(A) CRF1 accumulates in the nucleus upon
TOR inhibition. Cells were grown in SD me-
dium to midlog phase and treated with rapa-
mycin or drug vehicle alone for 30 min. CRF1
localization was examined by indirect immu-
nofluorescence on whole fixed cells. Strains
were as follow: WT, DM63; TOR1-1, DM72-
7A; CRF1-FHB, DM45-2C harboring plas-
mid pDM41. In all cases, CRF1 was tagged
with the HA epitope and a monoclonal anti-
HA antibody was used as a primary antibody
for indirect immunofluorescence.
(B) TOR controls CRF1 nuclear localization
via PKA and YAK1. Rapamycin-induced CRF1
nuclear accumulation is inhibited by constitu-
tively active RAS-PKA signaling (bcy1 and
RAS2Val19) or by deletion of YAK1 (yak1). Cells
were grown in SD medium to midlog phase,
treated with rapamycin or drug vehicle alone
for 30min, and examined by indirect immuno-
fluorescence. Strains were as follow: WT,
DM63; bcy1, DM79-7B; RAS2Val19, DM90-4B
harboring plasmid pTS118; yak1, DM71-9C.
TOR regulates FHL1. A model summarizing our findings and, thereby, a molecular link between the growth envi-
ronment and the regulation of ribosome biogenesis.and illustrating this mechanism is shown in Figure 7.
According to this model, TOR controls FHL1 via the The two FHL1 cofactors IFH1 and CRF1 contain a so-
called FHB (Forkhead binding) domain that binds theRAS-PKA-YAK1 effector pathway and the two FHL1 co-
factors IFH1, a coactivator, and CRF1, a corepressor. FHA domain in FHL1. The mutually exclusive binding of
IFH1 and CRF1 to FHL1 determines whether the Fork-Under favorable growth conditions, TOR signals via PKA
to inhibit the kinase YAK1. In the absence of active head factor, which is constitutively bound to target pro-
moters, acts as a transcriptional activator or repressor.YAK1, the corepressor CRF1 is cytoplasmic and inac-
tive. Consequently, IFH1binds FHL1 at RPgenepromot- The interplay of two opposing cofactors provides a
highly sensitive and fine-tunable regulatory mechanism.ers and activates transcription, possibly by recruiting
other transcription factors such as the histone acetylase The yeast Forkhead factor FKH2, via its FHA domain,
recruits the coactivator NDD1 to activate transcriptionsubunit ESA1. The binding of IFH1 to the promoter ap-
pears to be a key event in the expression of RP genes of cyclin genes, but in this case a corepressor remains
to be identified (Darieva et al., 2003; Koranda et al., 2000;since targeting IFH1 to a heterologous promoter is suffi-
cient to activate that promoter. Upon unfavorable Reynolds et al., 2003). To our knowledge, a Forkhead
cofactor other than IFH1, CRF1 and NDD1 has yet togrowth conditions, TOR and PKA are inactive and, con-
sequently, YAK1 is active. Active YAK1 phosphorylates be described in any organism. Thus, we propose a novel
mode of action for a Forkhead factor. Given the advan-CRF1. Phosphorylated CRF1 accumulates in the nu-
cleus and binds FHL1, thereby dislodging the coactiva- tages of opposing regulatory cofactors and the wide-
spread conservation of the FHA domain, we speculatetor IFH1 from RP gene promoters. The binding of CRF1
to promoter bound FHL1 may lead to repression of RP that the model proposed above for FHL1 will prove to
be a common paradigm.genes, firstly, by releasing the factors formerly recruited
by IFH1 and, secondly, by recruiting new factors such YAK1 is required for the nuclear localization of CRF1.
How does YAK1 control the nuclear localization ofas the histone deacetylase subunit RPD3. Consistent
with this notion, an RPD3 deletion confers rapamycin CRF1? YAK1 phosphorylates CRF1 and this phosphory-
lation coincideswith nuclear accumulationof CRF1. Fur-resistance and, as shown by others, the binding of ESA1
and RPD3 to RP gene promoters is inhibited and in- thermore, YAK1 phosphorylates the CRF1 FHB domain
which is required by CRF1 for both FHL1 binding andduced, respectively, by rapamycin (Humphrey et al.,
2004; Rohde and Cardenas, 2003). Thus, our findings nuclear accumulation. Finally, YAK1 like CRF1 also ac-
cumulates in the nucleus upon rapamycin treatmentprovide a pathway from TOR to RP gene expression
Cell
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Figure 6. YAK1 Phosphorylates and Activates CRF1
(A) YAK1 is required for RP gene repression upon TOR inhibition. Cells were grown in YPD to midlog phase and treated with either rapamycin
or drug vehicle alone for 30 min. RNA was extracted and Northern Blot analysis was performed with probes against the ribosomal protein
genes RPL30, RPL16, and RPS26A.
(B) YAK1 phosphorylates CRF1 in vivo. CRF1 was immunoprecipitated from extracts of rapamycin-treated or -untreated WT or yak1 cells and
subjected to immunoblotting analysis using anti-HA or anti-phosphothreonine antibodies.
(C) YAK1 phosphorylates CRF1 in vitro. YAK1 autophosphorylates and transphosphorylates CRF1 upon TOR inhibition. YAK1-myc was
immunopurified with antibodies directed against the myc epitope (see Experimental Procedures). As a control, a mock purification was
performed with cells expressing untagged YAK1. Cells expressing untagged (TB50a) or myc-tagged YAK1 (TS129-8C) were grown in YPD
medium and treated with rapamycin or drug vehicle alone for 30 min. The CRF1-FHB domain was expressed in E. coli as a GST fusion protein.
Equal amounts of the YAK1 kinase preparations and the CRF1-FHB fusion protein were used in each kinase reaction, as described in
Experimental Procedures. The reaction products (32P-labeled YAK1 and CRF1-FHB) were detected by autoradiography. YAK1 autophosphoryla-
tion (YAK1 P-Tyr) was also detected with antiphosphotyrosine antibody. Total YAK1-myc (YAK1) added to the reactions was detected by
immunoblotting. Total GST-CRF1-FHB (CRF1) was detected by Coomassie blue stain.
(D) YAK1 kinase activity is required for CRF1 phosphorylation in vitro. yak1 cells (TS127-1A) were transformed with plasmid pDM76 (YAK1)
or pDM72 (YAK1KD), grown in SD medium, and treated with rapamycin for 30 min. YAK1-HA and YAK1KD-HA (K398R) were immunopurified
with antibody directed against the HA epitope (see Experimental Procedures). Equal amounts of the YAK1 kinase and the CRF1-FHB fusion
protein were used in each kinase reaction, as described in Experimental Procedures. Otherwise experiment was performed as in 6C.
(Schmelzle et al., 2004). These observations suggest ylation of CRF1 stimulates the binding of CRF1 to FHL1,
to a factor mediating nuclear import, or to both. Thethat YAK1-mediated phosphorylation of CRF1 enhances
FHL1 binding and, thereby, nuclear retention of CRF1. significance of YAK1 nuclear accumulation also remains
to be determined.However, CRF1 still accumulates in the nucleus in the
absence of FHL1 (in an fhl1 strain). Furthermore, CRF1 Ribosome biogenesis requires the coordinated activ-
ity of all three RNA polymerases. How is Pol II-depen-still interactswith FHL1 in the two-hybrid systemwithout
rapamycin treatment (i.e., without YAK1 activation); pro- dent transcription of RP genes coordinated with Pol I-
andPol III-dependent transcription?Since the TOR-PKAviding CRF1 with a heterologous nuclear localization
signal, as in the two-hybrid system, is sufficient to obtain signaling pathway broadly controls ribosome biogene-
sis by regulating all three RNA polymerases (Powersan interaction with FHL1. These findings suggest that
YAK1 stimulates CRF1 nuclear import rather than reten- and Walter, 1999; Schmelzle et al., 2004; Zaragoza et
al., 1998), FHL1, IFH1, and CRF1 may also regulate Poltion. It remains to be determined whether the phosphor-
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Figure 7. Model of RP Gene Regulation by TOR and the Forkhead Transcription Factor FHL1
See Discussion for details.
Rapamycin was added to a final concentration of 200 ng/ml (200I and Pol III. Consistent with this notion, FHL1 was origi-
nM) from a 1mg/ml stock in 90% ethanol-10%Tween20. Rapamycinnally isolated as a multicopy suppressor of a mutation
treatment was always for 30 min unless otherwise indicated.affecting Pol III, and the FHL1 protein was subsequently
shown in two genome-wide interaction studies to inter-
Molecular Biology and Geneticsact with the Pol I transcription factor HMO1 (Ho et al.,
Restriction enzyme digestions, ligations, isolation of plasmids, PCR2002; Ito et al., 2001). Furthermore, RPD3 binds Pol
reactions, and DNA sequencing were performed by standard meth-
I-dependent promoters in addition to Pol II-dependent ods (Ausubel et al., 1998). PCR cassettes were used to generate
RP gene promoters (Humphrey et al., 2004; Rohde and gene deletions and modifications as described previously (Longtine
Cardenas, 2003; Tsang et al., 2003). These observations et al., 1998). To generate partial gene deletions of CRF1 and IFH1,
an overlap extension PCR technique was used as described pre-suggest that the TOR-PKA pathway may indeed coordi-
viously (Ho et al., 1989). Site-directed mutagenesis was performednate all three RNA polymerases via FHL1, IFH1, and
using the QuickChange method (Stratagene). All generated muta-CRF1.
tions were verified by PCR or DNA sequencing. Chromatin immuno-
TORsignals aspart of two structurally and functionally precipitation (ChIP) analyses were carried out as described pre-
distinct complexes, TORC1 and TORC2 (Loewith et al., viously (Hecht et al., 1996) with the following slight modifications.
2002). Only TORC1 is rapamycin sensitive, indicating PCR products were resolved on 2.5% agarose gels, visualized by
SYBRGREEN staining, and subsequently analyzed using Syngenethat TORC1mediates the regulationof ribosomebiogen-
Gene Quant and Gene Tool software. Cycle numbers and templateesis. TORC1, YAK1, and FHA domain-containing Fork-
concentrations were adjusted to ensure that PCR product formationhead transcription factors (MNF and ILF1/2 in human)
was in the linear range (22–35 cycles). Total chromatin input DNA
are conserved from yeast to human (Hara et al., 2002; was 1/20 to 1/500 of DNA used for ChIP analysis. Monoclonal anti-
Kim et al., 2002; Loewith et al., 2002; Durocher and bodies against the HA epitope (clone 12C5) and the myc epitope
Jackson, 2002) (D.E.M., A.S., M.N.H., unpublished ob- (clone 9E10) were used to precipitate epitope-tagged IFH1, CRF1,
and FHL1. Primers amplifying a 330 bp fragment of the RPL30 geneservation for YAK1), suggesting that the mechanism by
promoter were used. Primer pairs against a 200 bp fragment of thewhich TORC1 regulates ribosome biogenesis may, at
ACT1 coding region served as an internal control. The ACT1 controlleast in part, also be conserved.
PCR product after ChIP was not detected upon ChIP analysis under
the conditions used. Yeast two-hybrid analysis and quantitative
Experimental Procedures
-galactosidase assays were performed as described previously
(Ausubel et al., 1998; James et al., 1996). All positive interactions
Strains, Plasmids, and Media
were confirmed by retransformation of plasmids and analysis of
The Saccharomyces cerevisiae strains and plasmids used in this
-galactosidase expression upon loss of bait plasmids on 5-FOA
study are listed in Supplemental Tables S1 and S2 (available on Cell
plates.
website), respectively. All strains from our laboratory are isogenic
derivatives of TB50 or JK9-3d. The yeast two-hybrid analysis was
performed with strain PJ69-4A (James et al., 1996). Rich medium RNA Isolation and Northern Blot Analysis
RNA from cells treated with rapamycin or drug vehicle alone was(YPD) or synthetic medium (SD or SC) were prepared as described
previously (Beck et al., 1999; Sherman, 1991), with the exception that isolated as described previously (Schmitt et al., 1990). Probe synthe-
sis by PCR using digoxygenin-modified dUTP and subsequentthe synthetic media were supplemented with 0.2% yeast extract.
Cell
978
Northern Blot analysis was performed according to the manufactur- Cherel, I., and Thuriaux, P. (1995). The IFH1 gene product interacts
with a fork head protein in Saccharomyces cerevisiae. Yeast 11,er’s protocol (DIG labeling and detection, Roche).
261–270.
Coimmunoprecipitation and Immunoblotting Claypool, J.A., French, S.L., Johzuka, K., Eliason, K., Vu, L., Dodd,
Whole-cell extracts for SDS-PAGE analysis were prepared by glass J.A., Beyer, A.L., and Nomura, M. (2004). Tor pathway regulates
bead lysis as described previously (Beck et al., 1999). Lysis buffer Rrn3p-dependent recruitment of yeast RNA polymerase I to the
containing phosphatase and protease inhibitors were used as de- promoter but does not participate in alteration of the number of
scribed previously (Schmelzle et al., 2004). For detection of HA- and active genes. Mol. Biol. Cell 15, 946–956.
myc-tagged proteins, a mouse anti-HA antibody (clone 12CA5) or Cliften, P., Sudarsanam, P., Desikan, A., Fulton, L., Fulton, B., Ma-
mouse anti-myc antibody (clone 9E10) was used. For detection of jors, J., Waterston, R., Cohen, B.A., and Johnston, M. (2003). Finding
threonine phosphorylation an antiphosphothreonine antibody (Q7, functional features in Saccharomyces genomes by phylogenetic
Qiagen) was used. For detection of tyrosine phosphorylation an footprinting. Science 301, 71–76.
antiphosphotyrosine antibody was used (P-Tyr-100, Cell Signaling).
Darieva, Z., Pic-Taylor, A., Boros, J., Spanos, A., Geymonat, M.,Signals were detected using horseradish peroxidase-conjugated
Reece, R.J., Sedgwick, S.G., Sharrocks, A.D., and Morgan, B.A.secondary goat antimouse antibodies and ECL reagents (Amersham
(2003). Cell cycle-regulated transcription through the FHA domainPharmacia Biotech).
of Fkh2p and the coactivator Ndd1p. Curr. Biol. 13, 1740–1745.
Durocher, D., and Jackson, S.P. (2002). The FHA domain. FEBS Lett.Fluorescence Microscopy
513, 58–66.Fluorescence microscopy and indirect immunofluorescence on
Fath, S., Milkereit, P., Peyroche, G., Riva, M., Carles, C., andwhole fixed cells were performed as described previously (Schmel-
Tschochner, H. (2001). Differential roles of phosphorylation in thezle et al., 2004). Monoclonal anti-HA (12CA5) and anti-myc (9E10)
formation of transcriptional active RNA polymerase I. Proc. Natl.antibodies were used as the primary antibody to detect HA- and
Acad. Sci. USA 98, 14334–14339.myc-tagged proteins, respectively. Antibodieswere always checked
for specificity in each experiment using wild-type cells lacking the Garrett, S., and Broach, J. (1989). Loss of Ras activity in Saccharo-
corresponding epitope. myces cerevisiae is suppressed by disruptions of a new kinase
gene, YAKI, whose product may act downstream of the cAMP-
YAK1 Kinase Assay dependent protein kinase. Genes Dev. 3, 1336–1348.
myc-tagged YAK1 was purified from strain TS129-8C. A mock purifi- Gingras, A.C., Raught, B., and Sonenberg, N. (2001). Regulation of
cation was performedwith the isogenic derivative TB50a expressing translation initiation by FRAP/mTOR. Genes Dev. 15, 807–826.
untagged YAK1. YAK1-HA and YAK1KD-HA were purified from strain
Griffioen, G., Branduardi, P., Ballarini, A., Anghileri, P., Norbeck, J.,
TS127-1A (yak1) transformed with plasmid pDM76 (YAK1) or
Baroni, M.D., and Ruis, H. (2001). Nucleocytoplasmic distribution of
pDM72 (YAK1KD). Cells were grown in YPD and treated with rapa-
budding yeast protein kinase A regulatory subunit Bcy1 requires
mycin or drug vehicle alone for 30 min. Protein purification was
Zds1 and is regulated by Yak1-dependent phosphorylation of its
performed according to a standard protocol using coupled anti-
targeting domain. Mol. Cell. Biol. 21, 511–523.
myc-protein G-Sepharose or anti-HA protein A-Sepharose. The ex-
Hara, K., Maruki, Y., Long, X., Yoshino, K., Oshiro, N., Hidayat, S.,tended CRF1-FHB domain (amino acid residues 279–467), which
Tokunaga, C., Avruch, J., and Yonezawa, K. (2002). Raptor, a bindingwas shown to interact with FHL1 in a yeast two-hybrid analysis,
partner of target of rapamycin (TOR), mediates TOR action. Cellwas fused to glutathione-S-transferase (GST) usingplasmidpGEX4T
110, 177–189.(Amersham Pharmacia Biotech). Fusion protein expression was in-
duced with 1 mM IPTG for 4 hr in E. coli BL21 cells. Protein purifica- Hardwick, J.S., Kuruvilla, F.G., Tong, J.K., Shamji, A.F., and
tion was performed according to a standard protocol (Qiagen Ex- Schreiber, S.L. (1999). Rapamycin-modulated transcription defines
pressionist). Kinase reactions with varying substrate concentrations the subset of nutrient-sensitive signaling pathways directly con-
were performed as described (Moriya et al., 2001). GST and BSA trolled by the Tor proteins. Proc. Natl. Acad. Sci. USA 96, 14866–
were used as control substrates for the specificity of phosphory- 14870.
lation. Harris, T.E., and Lawrence, J.C., Jr. (2003). TOR signaling. Sci. STKE
212, re15.
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